Recce Pharmaceutical Ltd (ASS:RCE) has reached a milestone in its Phase II clinical trial to test the efficacy of its RECCE 327 topical gel for treatment of Acute Bacterial Skin and Skin Structure Infections (or ABSSSI) – with 20 of 30 total patients being dosed. Data taken from the trial indicates that the gel – also known as R327G – has yielded a strong effective response from participants, all of whom have reported positive outcomes after treatment, including total cure or notable improvement. At the same time, no Serious Adverse Events (SAEs) have been reported for the gel. Chief Medical A…